Maria Babak: The complexities of the blood-brain barrier and how it affects cancer treatment

Maria Babak shared a post by The Babak Lab on LinkedIn, adding:

“Let’s explore the complexities of the blood-brain barrier (BBB) and how it affects cancer treatment. If you’re curious about the challenges of delivering therapies to the brain and the innovative breakthroughs in this field, you won’t want to miss it. It covers exciting advancements like nanotechnology and focused ultrasound that are helping to overcome these barriers.

Why should you check it out?
It gives a clear and concise overview of why the BBB is both a protector and an obstacle, especially in treating aggressive brain cancers. Plus, you’ll get a glimpse into the future of cancer treatment.

Questions for you:
Have you ever wondered why treating brain cancers is so difficult?
What breakthrough treatment do you think holds the most promise for overcoming the BBB?”

Quoting The Babak Lab:

“Beyond the Barrier: Innovations in Cancer Treatment and the Blood-Brain Challenge.

The blood-brain barrier (BBB) plays a crucial role in protecting the brain but also creates significant challenges in treating brain cancers. This carousel explores:
– What the BBB is and how it works
– Why the BBB complicates cancer therapies
– Innovative solutions like nanotechnology, focused ultrasound, and immunotherapy

Curious how researchers are working to bypass this barrier and improve brain cancer treatment?
Swipe through the carousel to learn more!”

Source: Maria (Masha) Babak/LinkedIn and The Babak Lab/LinkedIn

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022. Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.